Ausgabe 3/2015
Inhalt (26 Artikel)
Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation
Katharina Mahal, Bernhard Biersack, Henrike Caysa, Rainer Schobert, Thomas Mueller
Convection-enhancement delivery of platinum-based drugs and LipoplatinTM to optimize the concomitant effect with radiotherapy in F98 glioma rat model
Minghan Shi, David Fortin, Léon Sanche, Benoit Paquette
Inhibition of human vascular endothelial cell migration and capillary-like tube formation by the microtubule-stabilizing agent peloruside A
Ariane Chan, A. Jonathan Singh, Peter T. Northcote, John H. Miller
Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro
Pushpendra Singh, Felix Bast
Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors
Sarah A. Holstein, James C. Bigelow, Richard D. Olson, Robert E. Vestal, Gerald M. Walsh, Raymond J. Hohl
A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors
Quincy Siu-Chung Chu, Randeep Sangha, Jennifer Spratlin, Larissa J. Vos, John R. Mackey, Alexander J. B. McEwan, Peter Venner, Evangelos D. Michelakis
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
Ahmad Awada, Herlinde Dumez, Philippe G. Aftimos, Jo Costermans, Sylvie Bartholomeus, Kathleen Forceville, Thierry Berghmans, Marie-Anne Meeus, Jessica Cescutti, Gerd Munzert, Korinna Pilz, Dan Liu, Patrick Schöffski
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer
David S. Hong, Filip Janku, Aung Naing, Gerald S. Falchook, Sarina Piha-Paul, Jennifer J. Wheler, Siqing Fu, Apostolia M. Tsimberidou, Michael Stecher, Prasant Mohanty, John Simard, Razelle Kurzrock
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer
Makoto Nishio, Atsushi Horiike, Hiroshi Nokihara, Hidehito Horinouchi, Shinji Nakamichi, Hiroshi Wakui, Fumiyoshi Ohyanagi, Keita Kudo, Noriko Yanagitani, Shunji Takahashi, Yasutoshi Kuboki, Noboru Yamamoto, Yasuhide Yamada, Masaichi Abe, Takashi Tahata, Tomohide Tamura
Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors
Shinji Nakamichi, Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Yutaka Fujiwara, Yosuke Tamura, Hiroshi Wakui, Kazunori Honda, Hidenori Mizugaki, Satoru Kitazono, Yuko Tanabe, Hajime Asahina, Naoya Yamazaki, Shigenobu Suzuki, Mieko Matsuoka, Yoshitaka Ogita, Tomohide Tamura
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
David C. Smith, Thea Kalebic, Jeffrey R. Infante, Lillian L. Siu, Daniel Sullivan, Gordana Vlahovic, John S. Kauh, Feng Gao, Allison J. Berger, Stephen Tirrell, Neeraj Gupta, Alessandra Di Bacco, Deborah Berg, Guohui Liu, Jianchang Lin, Ai-Min Hui, John A. Thompson
Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience
Akihito Kawazoe, Kohei Shitara, Shota Fukuoka, Masaaki Noguchi, Yasutoshi Kuboki, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Nozomu Fuse, Takayuki Yoshino, Atsushi Ohtsu, Toshihiko Doi
A phase 1 study of ABT-806 in subjects with advanced solid tumors
James M. Cleary, David A. Reardon, Nilofer Azad, Leena Gandhi, Geoffrey I. Shapiro, Jorge Chaves, Michelle Pedersen, Peter Ansell, William Ames, Hao Xiong, Wijith Munasinghe, Matt Dudley, Edward B. Reilly, Kyle Holen, Rod Humerickhouse
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies
A. Omlin, R. J. Jones, R. van der Noll, T. Satoh, M. Niwakawa, S. A. Smith, J. Graham, M. Ong, R. D. Finkelman, J. H. M. Schellens, A. Zivi, M. Crespo, R. Riisnaes, D. Nava-Rodrigues, M. D. Malone, C. Dive, R. Sloane, D. Moore, J. J. Alumkal, A. Dymond, P. A. Dickinson, M. Ranson, G. Clack, J. de Bono, T. Elliott
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors
Jennifer R. Diamond, Benjamin Wu, Neeraj Agarwal, Daniel W. Bowles, Elaine T. Lam, Theresa L. Werner, Erik Rasmussen, Erick Gamelin, Felipe Soto, Greg Friberg, Yu-Nien Sun, Sunil Sharma
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy
Heloisa Veasey Rodrigues, Danxia Ke, JoAnn Lim, Bettzy Stephen, Jorge Bellido, Filip Janku, Ralph Zinner, Apostolia Tsimberidou, David Hong, Sarina Piha-Paul, Siqing Fu, Aung Naing, Vivek Subbiah, Daniel Karp, Gerald Falchook, Razelle Kurzrock, Jennifer Wheler
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer
Analia Azaro, Jordi Rodon, Antonio Calles, Irene Braña, Manuel Hidalgo, Pedro P. Lopez-Casas, Manuel Munoz, Paul Westwood, Joel Miller, Brian A. Moser, Ute Ohnmacht, William Bumgardner, Karim A. Benhadji, Emiliano Calvo
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
Khanh Do, Giovanna Speranza, Rachel Bishop, Sonny Khin, Larry Rubinstein, Robert J. Kinders, Manuel Datiles, Michelle Eugeni, Michael H. Lam, L. Austin Doyle, James H. Doroshow, Shivaani Kummar
Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors
Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Naoya Kanogawa, Tomoko Saito, Tenyu Motoyama, Eiichiro Suzuki, Akinobu Tawada, Fumihiko Kanai, Osamu Yokosuka
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations
Takayuki Yoshino, Yoshito Komatsu, Yasuhide Yamada, Kentaro Yamazaki, Akihito Tsuji, Takashi Ura, Axel Grothey, Eric Van Cutsem, Andrea Wagner, Frank Cihon, Yoko Hamada, Atsushi Ohtsu
Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer
Daniel J. Crona, Young E. Whang
The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients
Satoru Miura, Kyoichi Kaira, Rieko Kaira, Hiroaki Akamatsu, Akira Ono, Takehito Shukuya, Asuka Tsuya, Yukiko Nakamura, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi, Masahiro Endo, Nobuyuki Yamamoto
The oncolytic virus, pelareorep, as a novel anticancer agent: a review
Romit Chakrabarty, Hue Tran, Giovanni Selvaggi, Allison Hagerman, Brad Thompson, Matt Coffey
3,4′,5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency
Fahad S. Aldawsari, Carlos A. Velázquez-Martínez
Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer therapy?
José Manuel Calderón-Montaño, Estefanía Burgos-Morón, Emilio Guillén-Mancina, Miguel López-Lázaro
Response to: Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer?
Robert A. Newman, Peiying Yang